Viking Therapeutics appoints Dorothy Gemmell to board of directors

Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX

0.00

  • Viking Therapeutics appointed Dorothy Gemmell to its board, effective immediately.
  • Gemmell brings over 25 years in healthcare, digital health, commercialization; held president or chief commercial officer roles at GoodRx, Capsule, Havas Life.
  • Appointment comes as Viking advances next-generation metabolic programs, including preparations for a potential launch of obesity drug candidate VK2735.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA10817) on July 23, 2026, and is solely responsible for the information contained therein.